<DOC>
	<DOCNO>NCT00575588</DOCNO>
	<brief_summary>Saxagliptin new investigational medication develop treatment type 2 diabetes . This study design assess efficacy tolerability saxagliptin addition metformin compare sulphonylurea addition metformin .</brief_summary>
	<brief_title>52-week add-on Metformin Comparison Saxagliptin Sulphonylurea , With 52-week Extension Period</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes , Treatment metformin alone stable dos 1500 mg high per day least 8 week prior Visit 1 , HbA1c &gt; 6.5 % â‰¤10.0 % Type 1 diabetes , history diabetic ketoacidosis hyperosmolar nonketonic coma , Insulin therapy within one year enrolment ( exception insulin therapy hospitalization use gestational diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>DPP-4 Inhibitors</keyword>
	<keyword>HbA1c</keyword>
	<keyword>incretins</keyword>
</DOC>